Thermo Fisher Scientific Inc. (TMO) to Acquire Clario in $9.4 Billion Deal

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best stocks to invest in, according to billionaire D.E. Shaw. On October 29, Thermo Fisher announced plans to buy Clario, a private data management firm, for up to $9.4 billion. The deal includes an upfront payment of $8.88 billion, with additional payouts tied to Clario’s performance through 2027.

Thermo Fisher Scientific Inc. (TMO) to Acquire Clario in $9.4 Billion Deal

This marks Thermo’s third major acquisition in 2025, aimed at boosting its clinical trial research capabilities as U.S. demand rebounds. Clario, based in Philadelphia, specializes in tools for analyzing and managing clinical trial data. The acquisition is expected to close in early 2026 and add $0.45 to adjusted earnings in its first year.

Earlier on October 16, Thermo Fisher Scientific Inc. inked a strategic collaboration with OpenAI to enhance its growth strategy through AI integration. The partnership comes as the company seeks to leverage AI to accelerate and improve the success of drug development while also making it easier for customers to access medicines faster and more cost-effectively. Working with OpenAI, the company is to accelerate scientific innovation while also enhancing productivity and reducing complexity.

Thermo Fisher Scientific Inc. (NYSE:TMO) develops and supplies a vast range of products and services for scientific research, analysis, and diagnostics. It offers laboratory equipment, chemicals, and supplies, as well as advanced technologies and services for life sciences research, drug development, and pharmaceutical manufacturing.

While we acknowledge the potential of TMO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TMO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 8 Long-Term Biotechnology Stocks to Buy and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.

Disclosure: None. This article is originally published at Insider Monkey.